The major cause of congenital adrenal hyperplasia (CAH), a common recessive genetic disease, is the deficiency of steroid 21-hydroxylase (210H), a microsomal enzyme encoded by the CYP21 gene. Although several CAH causing mutations have been identified in the CYP21 gene of patients with 210H deficiency, genotyping of the 210H locus is quite complex because ofthe high frequency of gene conversion and the presence of multiple mutations on single CAH alleles. In order to perform the complete characterisation of the CYP21 gene coding region more simply, we developed a highly sensitive, non-radioactive method allowing DNA single strand conformation polymorphism (DNA-SSCP) analysis. This method was applied to the characterisation of all the exons and intron-exon junctions of the CYP21 gene in five patients affected by the simple virilising form and one affected by the salt wasting form. In all samples showing SSCP signals, direct sequence analysis showed the presence of more than one single sequence variant. In particular, four mutations which are already known to cause the disease, 16 polymorphisms, and one newly identified C to T transition at position 849 were detected. A random sequence analysis, performed on 31 out of 81 exons showing a normal SSCP pattern, shows the method to be highly sensitive: no sequence variant was detected, thus confirming the validity of this non-radioactive DNA-SSCP analysis in characterising the CYP21 gene in patients with steroid 210H deficiency.
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Notwithstanding the complete characterisation of all exons and exon/intron junctions of the CYP21 gene, no complete genotype/phenotype correlation was found in the panel of patients analysed, thus suggesting that characterisation of CAH alleles must be extended to outside the coding region of the CYP21 gene, most probably into the promoter region.
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Congenital adrenal hyperplasia (CAH) is a
common recessive genetic disease whose main cause is steroid 21- 21 12 structure. 2 In the light of this, direct sequencing of the entire gene seems to be the best way to characterise fully a 210H deficiency patient. Alternatively, the radioactive DNA-SSCP method has been used to analyse only part of the gene. 23 In The three gene specific fragments were used as a template for the amplification of the 10 exons and all the exon/intron junctions of the CYP21 gene. The relevant primer pairs are listed in table 1, together with the annealing temperature used for the amplification of each exon in 25 polymerisation cycles (30 seconds at 94°C, 30 seconds annealing, 30 seconds at 72°C). A total of 11 amplified fragments were obtained since exon 8 was split into two fragments. Subsequently, 1 pl of the amplification mixture of each exon and exon/intron junction was mixed with 9 I1 of a denaturing solution containing 95% (v/v) formamide, 0.05% w/v of both bromophenol blue and xylencianol, 0.1 N NaOH, 20 mmol/l EDTA, pH 8.0, and underwent SSCP analysis.24 After 10 minutes incubation at 96°C, the samples were cooled in a 4°C ice bath and electrophoresed in TBE buffer at 10 mA for three to four hours. In order to analyse SSCP patterns, minigels containing different percentages of acrylamide, bisacrylamide, and glycerol were used. Gels were stained using standard silver nitrate staining (Bio-Rad Lab).
All the PCR products showing positive SSCP pattern were purified with the Quiaquick kit (Quiagen) and directly sequenced using the Sequenase version 2.0 kit (Amersham). this purpose, including 18 newly designed oligonucleotides, are shown in table 1, with the respective amplification fragments ranging in size from 238 to 386 bp.
Results
To perform DNA-SSCP analysis, different electrophoretic conditions were set up for each one of the amplified DNA fragments. Thus, to detect abnormal SSCP patterns in exons 1, 2, 7, 9, 10, and in the 5' portion of exon 8, minigels containing 10% acrylamide with 2.0% crosslinking and 5% glycerol were used and the electrophoretic run was performed at room temperature. For analysis of exons 3 and 6, the gel electrophoresis was run under the same conditions reported above but without glycerol and with 12% and 10% acrylamide, respectively, while in the case of exon 4, a minigel with 7% acrylamide, 2.5% crosslinking, and 5% glycerol was run at 4°C. Electrophoretic band shift, owing to single strand conformation polymorphism, was detected in all but exon 5 and the 3' portion of exon 8, for which no difference in the mobility of the single strand was detected after running gels with either 2.0 or 2.5% crosslinking both in the presence or absence of glycerol. All samples showing SSCP signals were purified from agarose gels and directly sequenced. As expected, the presence of a number of sequence variants was shown (fig 2) . On the other hand, 31 out of 81 amplified fragments showing normal SSCP patterns were purified from agarose and directly sequenced. These samples were randomly chosen from among the subjects and analysed in such a way that for each exon about 50% of the negative signals were sequenced. This strategy was also applied in the case of exon 5 and the 3' end of exon 8, the only two exons showing no SSCP signals in the experimental conditions used. Sequence analysis of these negative SSCP samples did not show any nucleotide variations as compared to the sequence of the normal allele,5 thus confirming that no sequence variant was lost in our procedure and showing the high sensitivity of the method.
The complete genotypes of the CYP21 alleles in the three families and two single patients analysed according to this method are shown in table 2. For each patient at least one of the known disease causing mutations was identified together with a number of other sequence variants. In particular, the four mutations I2 splice, I172N, cluster E6, and Q318X were found. They have been previously described as causing the disease on the basis of in vitro mutagenesis and expression studies to predict the degree of enzyme deficiency for each mutation.8 15 26 A T->C transition at base 395 in intron 2, which has not been excluded as affecting gene expression,25 was also identified.
Six silent mutations, L39L, P45P, D234D, S374S, L248L, and P490P, which apparently do not cause changes in amino acid composition were also found. Other nucleotides that varied among the CYP21 alleles analysed include a C-4T transition four bases upstream of the initiation codon, deletion of Leul0, five intron substitutions (c-*a 419, t-*c 453, c-ot 860, a-*g 1420, and c-ot 1421), and two sequence variations leading to amino acid changes (K102R and N493S Although the DNA-SSCP method described here proved to be an efficient system for characterising the CYP2 1 gene in patients affected by 21 
